ES2629317T3 - Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina - Google Patents
Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina Download PDFInfo
- Publication number
- ES2629317T3 ES2629317T3 ES14164565.5T ES14164565T ES2629317T3 ES 2629317 T3 ES2629317 T3 ES 2629317T3 ES 14164565 T ES14164565 T ES 14164565T ES 2629317 T3 ES2629317 T3 ES 2629317T3
- Authority
- ES
- Spain
- Prior art keywords
- combination
- treatment
- administration
- brain tumors
- rapamycin derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title abstract description 4
- 208000003174 Brain Neoplasms Diseases 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001926 lymphatic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
40-O-(2-hidroxietil)-rapamicina para su uso como principio activo único en el tratamiento de tumores cerebrales sólidos distintos de cáncer linfático.
Description
5
10
15
20
25
30
35
40
45
50
55
hipertermia leve prolongada de todo el cuerpo y/o terapia de irradiación.
La administración de una combinación farmacéutica de la descripción no solo da como resultado un efecto beneficioso, por ejemplo, un efecto terapéutico sinérgico, por ejemplo con respecto a la ralentización, detención o inversión de la formación de neoplasias o una duración más larga de la respuesta frente al tumor, sino también efectos beneficiosos sorprendentes adicionales, por ejemplo menos efectos secundarios, una calidad de vida mejorada o una mortandad y morbilidad disminuidas, en comparación con una monoterapia que aplica solo uno de los principios farmacéuticamente activos usados en la combinación de la descripción, en particular en el tratamiento de un tumor que es refractario a otros agentes quimioterápicos conocidos como agentes anticancerígenos. En particular, se observa una absorción aumentada del coagente (b) en el tejido tumoral y las células tumorales, cuando se aplica en combinación con el primer agente (a).
Un beneficio adicional es que pueden usarse dosis más bajas de los principios activos de la combinación de la invención, por ejemplo, que las dosificaciones a menudo no sólo tienen que ser más pequeñas, sino que también se aplican con menor frecuencia, o pueden usarse para disminuir la incidencia de los efectos secundarios, mientras se controla el crecimiento de la formación de neoplasias. Esto es según los deseos y requerimientos de los pacientes que van a tratarse.
Los términos “coadministración” o “administración combinada” o similares tal como se usan en el presente documento se entiende que abarcan la administración de los agentes terapéuticos seleccionados a un solo paciente, y se pretende que incluyan regímenes de tratamiento en los que los agentes no se administran necesariamente por la misma vía de administración o al mismo tiempo.
Las composiciones farmacéuticas para la administración separada del primer agente a) y el coagente b) y para la administración en una combinación fija, es decir, una única composición galénica que comprende al menos dos componentes de combinación a) y b), según la invención pueden prepararse de manera conocida per se y son las adecuadas para la administración entérica, tal como oral o rectal, y parenteral a mamíferos (animales de sangre caliente), incluyendo seres humanos, que comprende una cantidad terapéuticamente eficaz de al menos un componente de combinación farmacológicamente activo solo, por ejemplo tal como se indica anteriormente, o en combinación con uno o más portadores o diluyentes farmacéuticamente aceptables, especialmente adecuados para la aplicación entérica o parenteral.
Las composiciones farmacéuticas adecuadas contienen, por ejemplo, de desde aproximadamente el 0,1% hasta aproximadamente el 99,9%, preferiblemente desde aproximadamente el 1% hasta aproximadamente el 60%, del/de los principio(s) activo(s). Las preparaciones farmacéuticas para la terapia de combinación para la administración entérica o parenteral son, por ejemplo, aquellas en formas de dosificación unitarias, tales como comprimidos recubiertos con azúcar, comprimidos, cápsulas o supositorios, o ampollas. Si no se indica lo contrario, estos se preparan de manera conocida per se, por ejemplo por medio de procesos de mezclado, granulación, recubrimiento con azúcar, disolución o liofilización convencionales. Se apreciará que el contenido unitario de un componente de combinación contenido en una dosis individual de cada forma de dosificación no necesita por sí mismo constituir una cantidad eficaz puesto que la cantidad eficaz necesaria puede alcanzarse mediante la administración de una pluralidad de unidades de dosificación.
Una cantidad terapéuticamente eficaz de cada uno de los componentes de combinación de la combinación dada a conocer en el presente documento puede administrarse simultánea o secuencialmente y en cualquier orden, y los componentes pueden administrarse por separado o como una combinación fija. Por ejemplo, el método de retraso del avance o tratamiento de una enfermedad maligna proliferativa según la descripción puede comprender (i) la administración del primer agente a) en forma de sal libre o farmacéuticamente aceptable y (ii) la administración de un coagente b) en forma de sal libre o farmacéuticamente aceptable, simultánea o secuencialmente en cualquier orden, en cantidades conjuntamente eficaces de manera terapéutica, preferiblemente en cantidades sinérgicamente eficaces, por ejemplo, en dosificaciones diarias o intermitentes correspondientes a las cantidades descritas en el presente documento. Los componentes de combinación individuales de la combinación dada a conocer en el presente documento pueden administrarse por separado en diferentes momentos durante el transcurso de la terapia
o de manera concurrente en formas de combinación divididas o únicas. Además, el término administración también abarca el uso de un profármaco de un componente de combinación que se convierte in vivo en el componente de la combinación como tal. Por tanto, la presente descripción debe entenderse como que abarca todos estos regímenes de tratamiento simultáneo o alternativo y el término “que administra” ha de interpretarse en consecuencia.
La dosificación eficaz de cada uno de los componentes de combinación empleados en la combinación dada a conocer en el presente documento puede variar según el compuesto o composición farmacéutica particular empleada, el modo de administración, el estado que se está tratando, la gravedad del estado que se está tratando. Por tanto, el régimen de dosificación de la combinación dada a conocer en el presente documento se selecciona según una variedad de factores incluyendo la vía de administración y la función renal y hepática del paciente. Un médico, clínico o veterinario experto puede determinar y recomendar fácilmente la cantidad eficaz de los principios activos individuales requeridos para prevenir, contrarrestar o detener el avance del estado. La precisión óptima para
8
Claims (1)
-
imagen1
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0104072 | 2001-02-19 | ||
GB0104072A GB0104072D0 (en) | 2001-02-19 | 2001-02-19 | Organic compounds |
GB0124957A GB0124957D0 (en) | 2001-10-17 | 2001-10-17 | Organic compounds |
GB0124957 | 2001-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2629317T3 true ES2629317T3 (es) | 2017-08-08 |
Family
ID=26245731
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES18155724T Expired - Lifetime ES2744377T3 (es) | 2001-02-19 | 2002-02-18 | Derivado de rapamicina para tratar cáncer de páncreas |
ES16186041T Expired - Lifetime ES2705016T3 (es) | 2001-02-19 | 2002-02-18 | Derivado de rapamicina para el tratamiento de cáncer de pulmón |
ES10174983.6T Expired - Lifetime ES2543383T3 (es) | 2001-02-19 | 2002-02-18 | Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano |
ES14164259.5T Expired - Lifetime ES2640787T3 (es) | 2001-02-19 | 2002-02-18 | Combinación de un derivado de rapamicina y letrozol para tratar el cáncer de mama |
ES18155722T Expired - Lifetime ES2921798T3 (es) | 2001-02-19 | 2002-02-18 | Derivado de rapamicina para el tratamiento de tumores sólidos |
ES14164565.5T Expired - Lifetime ES2629317T3 (es) | 2001-02-19 | 2002-02-18 | Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina |
ES10174985.1T Expired - Lifetime ES2600304T3 (es) | 2001-02-19 | 2002-02-18 | Tratamiento de tumores sólidos de riñón con un derivado de rapamicina |
ES18155644T Expired - Lifetime ES2728739T3 (es) | 2001-02-19 | 2002-02-18 | Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES18155724T Expired - Lifetime ES2744377T3 (es) | 2001-02-19 | 2002-02-18 | Derivado de rapamicina para tratar cáncer de páncreas |
ES16186041T Expired - Lifetime ES2705016T3 (es) | 2001-02-19 | 2002-02-18 | Derivado de rapamicina para el tratamiento de cáncer de pulmón |
ES10174983.6T Expired - Lifetime ES2543383T3 (es) | 2001-02-19 | 2002-02-18 | Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano |
ES14164259.5T Expired - Lifetime ES2640787T3 (es) | 2001-02-19 | 2002-02-18 | Combinación de un derivado de rapamicina y letrozol para tratar el cáncer de mama |
ES18155722T Expired - Lifetime ES2921798T3 (es) | 2001-02-19 | 2002-02-18 | Derivado de rapamicina para el tratamiento de tumores sólidos |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10174985.1T Expired - Lifetime ES2600304T3 (es) | 2001-02-19 | 2002-02-18 | Tratamiento de tumores sólidos de riñón con un derivado de rapamicina |
ES18155644T Expired - Lifetime ES2728739T3 (es) | 2001-02-19 | 2002-02-18 | Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada |
Country Status (27)
Country | Link |
---|---|
US (10) | US8410131B2 (es) |
EP (11) | EP3345602B1 (es) |
JP (14) | JP2004525899A (es) |
KR (3) | KR20050095906A (es) |
CN (5) | CN1296043C (es) |
AU (1) | AU2002250968C1 (es) |
BR (1) | BR0207378A (es) |
CA (3) | CA2994779C (es) |
CY (11) | CY1116616T1 (es) |
CZ (5) | CZ309178B6 (es) |
DK (6) | DK2762140T3 (es) |
ES (8) | ES2744377T3 (es) |
HK (7) | HK1146247A1 (es) |
HU (1) | HUP0303271A3 (es) |
IL (13) | IL157425A0 (es) |
LT (9) | LT2762140T (es) |
LU (3) | LU92880I2 (es) |
MX (3) | MXPA03007418A (es) |
NO (14) | NO333105B1 (es) |
NZ (1) | NZ527692A (es) |
PL (5) | PL409579A1 (es) |
PT (7) | PT3351246T (es) |
RU (8) | RU2322981C2 (es) |
SI (6) | SI3342411T1 (es) |
SK (5) | SK288545B6 (es) |
TW (2) | TW200626151A (es) |
WO (1) | WO2002066019A2 (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
AU2725000A (en) | 1999-01-13 | 2000-08-01 | Bayer Corporation | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
LT2762140T (lt) | 2001-02-19 | 2017-06-26 | Novartis Ag | Solidinių smegenų navikų gydymas rapamicino dariniu |
PL367267A1 (en) * | 2001-06-01 | 2005-02-21 | Wyeth | Antineoplastic combinations |
MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
US8383605B2 (en) | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
PL375493A1 (en) * | 2002-07-30 | 2005-11-28 | Zentaris Gmbh | Use of alkyl phosphocholines in combination with antitumor medicaments |
US7846141B2 (en) | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
WO2004032923A1 (en) * | 2002-10-11 | 2004-04-22 | Dana-Farber Cancer Institute Inc | Epothilone derivatives for the treatment of multiple myeloma |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
ES2494915T3 (es) * | 2004-02-23 | 2014-09-16 | Novartis Ag | P53 natural como biomarcador para el tratamiento con inhibidores de mTOR en combinación con un agente citotóxico |
GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
BRPI0508959A (pt) * | 2004-03-23 | 2007-08-14 | Astrazeneca Ab | uso de azd2171 ou de um sal do mesmo farmaceuticamente aceitável, uso de sal maleato de azd2171 e oxaliplatina, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
AU2006213588B2 (en) | 2005-02-09 | 2011-11-17 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for treatment of diseases or conditions |
CN102357104B (zh) * | 2005-03-07 | 2016-01-27 | 罗巴斯研究机构 | 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用 |
GB0504995D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
RU2443418C2 (ru) * | 2005-07-20 | 2012-02-27 | Новартис Аг | КОМБИНАЦИЯ ПИРИМИДИЛАМИНОБЕНЗАМИДА И ИНГИБИТОРА КИНАЗ mTOR |
CN102579467A (zh) | 2005-11-14 | 2012-07-18 | 阿里亚德医药股份有限公司 | 雷帕霉素衍生物在治疗癌症中的用途 |
KR20080071600A (ko) * | 2005-11-21 | 2008-08-04 | 노파르티스 아게 | Mtor 억제제를 사용하는 신경내분비 종양 치료법 |
GB0602123D0 (en) * | 2006-02-02 | 2006-03-15 | Novartis Ag | Organic compounds |
JP5639743B2 (ja) | 2006-02-02 | 2014-12-10 | ノバルティス アーゲー | 結節性硬化症処置 |
US8492400B2 (en) | 2006-02-09 | 2013-07-23 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
CN103127100A (zh) | 2006-03-23 | 2013-06-05 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂和方法 |
MX2008012715A (es) * | 2006-04-05 | 2008-10-14 | Novartis Ag | Combinaciones de agentes terapeuticos para el tratamiento de cancer. |
CA2661024A1 (en) * | 2006-08-28 | 2008-03-06 | The Regents Of The University Of California | Small molecule potentiator of hormonal therapy for breast cancer |
US9820888B2 (en) | 2006-09-26 | 2017-11-21 | Smith & Nephew, Inc. | Wound dressing |
JP2010520289A (ja) * | 2007-03-07 | 2010-06-10 | アブラクシス バイオサイエンス, エルエルシー | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
CN101292980B (zh) * | 2007-04-28 | 2010-11-10 | 上海交通大学医学院附属仁济医院 | 一种含有雷帕霉素的用于治疗大肠癌的药物组合物 |
JP2010536738A (ja) * | 2007-08-16 | 2010-12-02 | バイオコンパティブルズ ユーケー リミテッド | 薬剤の組み合わせの送達 |
US20090149511A1 (en) * | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
US8298200B2 (en) | 2009-06-01 | 2012-10-30 | Tyco Healthcare Group Lp | System for providing continual drainage in negative pressure wound therapy |
US20120040896A1 (en) * | 2008-04-11 | 2012-02-16 | The Regents Of The University Of Colorado | Compositions, methods and uses for modulation of brca 1 |
US8338569B2 (en) * | 2008-08-04 | 2012-12-25 | Five Prime Therapeutics, Inc. | FGFR extracellular domain acidic region muteins |
GB0902368D0 (en) | 2009-02-13 | 2009-04-01 | Smith & Nephew | Wound packing |
GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
US8791315B2 (en) | 2010-02-26 | 2014-07-29 | Smith & Nephew, Inc. | Systems and methods for using negative pressure wound therapy to manage open abdominal wounds |
CA2794513A1 (en) | 2010-03-31 | 2011-10-06 | Aeterna Zentaris Gmbh | Perifosine and capecitabine as a combined treatment for cancer |
PT2606070T (pt) | 2010-08-20 | 2017-03-31 | Novartis Ag | Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3) |
MX362521B (es) | 2011-12-05 | 2019-01-22 | Novartis Ag | Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3). |
EP2852418B1 (en) | 2012-05-23 | 2018-04-18 | Smith & Nephew PLC | Apparatuses for negative pressure wound therapy |
HUE033329T2 (en) | 2012-08-01 | 2017-11-28 | Smith & Nephew | dressing |
US10076449B2 (en) | 2012-08-01 | 2018-09-18 | Smith & Nephew Plc | Wound dressing and method of treatment |
RU2015143729A (ru) | 2013-03-15 | 2017-04-21 | СМИТ ЭНД НЕФЬЮ ПиЭлСи | Раневая повязка и способ лечения |
US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
WO2016066608A1 (en) | 2014-10-28 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging |
LT3640345T (lt) * | 2015-08-17 | 2022-01-10 | Kura Oncology, Inc. | Vėžiu sergančių pacientų gydymo būdai farneziltransferazės inhibitoriais |
CN109195601A (zh) * | 2016-03-15 | 2019-01-11 | 迪美公司 | 用于治疗癌症的药物组合物 |
EP3548894B1 (en) | 2016-12-02 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for diagnosing renal cell carcinoma |
US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
CA3049435A1 (en) | 2017-01-09 | 2018-07-12 | Scott Grindrod | Selective histone deacetylase inhibitors for the treatment of human disease |
JP7217241B2 (ja) | 2017-06-30 | 2023-02-02 | ティージェイ スミス アンド ネフュー リミテッド | 陰圧創傷治療装置 |
WO2019089556A1 (en) * | 2017-10-31 | 2019-05-09 | Steve Gorlin | Combinations of chemotherapeutic agents and antimicrobial particles and uses thereof |
CA3087565A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
IL312291A (en) | 2018-05-01 | 2024-06-01 | Revolution Medicines Inc | C-26-linked rapamycin analogs as MTOR inhibitors |
WO2019212990A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors |
CN108825638A (zh) * | 2018-08-01 | 2018-11-16 | 安徽送变电工程有限公司 | 一种应用于螺纹工件的防盗装置 |
GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
EA202193111A1 (ru) | 2019-05-14 | 2022-02-10 | Тайм, Инк. | Композиции и способы для лечения рака |
US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
KR20230053539A (ko) | 2021-10-14 | 2023-04-21 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물 |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US876165A (en) | 1904-05-11 | 1908-01-07 | George K Woodworth | Wireless telegraph transmitting system. |
GB104072A (en) | 1916-04-14 | 1917-02-22 | William Henry Nosworthy | Apparatus for Lighting Fires or Heating or other purposes. |
GB124957A (en) | 1918-06-04 | 1919-04-10 | Frederick William Miller | Improvement in Glass Moulding. |
GB1524747A (en) * | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
DE3372965D1 (en) | 1982-07-23 | 1987-09-17 | Ici Plc | Amide derivatives |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
GB8517360D0 (en) | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) * | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
JP3140228B2 (ja) * | 1992-02-17 | 2001-03-05 | ファイザー製薬株式会社 | 新規な大環状ラクトンおよびその生産菌 |
TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US5256790A (en) * | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
AU5151093A (en) | 1992-10-14 | 1994-05-09 | Unichema Chemie Bv | Process for the preparation of alkylglycosides |
DK1167384T3 (da) | 1992-10-28 | 2007-04-10 | Genentech Inc | Vaskular endotheliel cellevækstfaktor antagonister |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
DE4301781C2 (de) | 1993-01-23 | 1995-07-20 | Lohmann Therapie Syst Lts | Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
GB9325400D0 (en) | 1993-12-11 | 1994-02-16 | Sarll David P G | Temperature recorder |
SK78196A3 (en) | 1993-12-17 | 1997-02-05 | Sandoz Ag | Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them |
WO1995028156A1 (en) * | 1994-04-14 | 1995-10-26 | Sepracor, Inc. | Treating estrogen-dependent diseases with (-)-fadrozole |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
GB9417873D0 (en) | 1994-09-06 | 1994-10-26 | Sandoz Ltd | Organic compounds |
PE52896A1 (es) | 1994-10-26 | 1996-12-12 | Novartis Ag | Composicion farmaceutica |
EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
RU2158267C2 (ru) * | 1995-06-09 | 2000-10-27 | Новартис Аг | Производные рапамицина и фармацевтическая композиция на их основе |
HUP9900330A3 (en) | 1995-07-06 | 2001-08-28 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5567831A (en) * | 1995-08-16 | 1996-10-22 | Duguesne University Of The Holy Ghost | Non-steroidal sulfatase inhibitor compounds and their method of use |
DE19544507B4 (de) * | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
ES2174250T5 (es) | 1996-04-12 | 2010-04-21 | Warner-Lambert Company Llc | Inhibidores irreversibles de tirosina quinasas. |
ATE233098T1 (de) * | 1996-06-11 | 2003-03-15 | Novartis Ag | Kombination eines somatostatin analogs und eines rapamycins |
WO1997049688A1 (en) | 1996-06-24 | 1997-12-31 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
US5922730A (en) | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
CA2266039A1 (en) | 1996-09-09 | 1998-03-12 | Thomas Joseph Caggiano | Alkylated rapamycin derivatives |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
EP0954315A2 (en) | 1996-09-13 | 1999-11-10 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
GB9619631D0 (en) | 1996-09-20 | 1996-11-06 | British Biotech Pharm | Combination therapy |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US5985325A (en) | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
US6015815A (en) * | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6152347A (en) | 1998-01-30 | 2000-11-28 | Acco Brands, Inc. | Vertical Stapler |
SI1064942T1 (en) | 1998-03-26 | 2004-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Sustained release preparation of a macrolide |
US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
AU749475B2 (en) * | 1998-04-27 | 2002-06-27 | Astellas Pharma Inc. | Medicinal compositions |
CA2339961C (en) | 1998-08-11 | 2009-01-20 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
IL143596A0 (en) | 1998-12-22 | 2002-04-21 | Genentech Inc | Vascular endothelial cell growth factor antagonists and uses thereof |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
ATE329596T1 (de) | 1999-03-30 | 2006-07-15 | Novartis Pharma Gmbh | Phthalazinderivate zur behandlung von entzündlicher erkrankungen |
US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
GB9911582D0 (en) * | 1999-05-18 | 1999-07-21 | Pharmacia & Upjohn Spa | Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound |
EP1074265A1 (en) | 1999-08-03 | 2001-02-07 | Erasmus Universiteit Rotterdam | Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility |
ES2222222T3 (es) | 1999-08-18 | 2005-02-01 | Wyeth | Esteres hidrosolubles de sdz-rad. |
AU2292801A (en) | 1999-12-22 | 2001-07-03 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Compositions and methods for treatment of breast cancer |
US6899731B2 (en) | 1999-12-30 | 2005-05-31 | Boston Scientific Scimed, Inc. | Controlled delivery of therapeutic agents by insertable medical devices |
AU3095601A (en) * | 2000-01-14 | 2001-07-24 | Univ Pennsylvania | O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
US6641811B1 (en) * | 2000-02-10 | 2003-11-04 | Cornell Research Foundation, Inc. | Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression |
GB0005257D0 (en) | 2000-03-03 | 2000-04-26 | Pharmacia & Upjohn Spa | Breast cancer hormonal therapy |
US6761895B2 (en) | 2000-04-17 | 2004-07-13 | Yamanouchi Pharmaceutical Co., Ltd. | Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
US20020013335A1 (en) | 2000-06-16 | 2002-01-31 | American Home Products Corporation | Method of treating cardiovascular disease |
GB0017635D0 (en) | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
MXPA03001245A (es) | 2000-08-11 | 2003-05-27 | Wyeth Corp | Metodo para el tratamiento del carcionma positivo para receptores de estrogeno. |
US20050004007A1 (en) * | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
WO2002028387A1 (en) * | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
AU2002239436B2 (en) | 2000-10-31 | 2007-04-26 | Cook Medical Technologies Llc | Coated implantable medical device |
TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
AU2002249826A1 (en) * | 2000-12-22 | 2002-07-30 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
LT2762140T (lt) | 2001-02-19 | 2017-06-26 | Novartis Ag | Solidinių smegenų navikų gydymas rapamicino dariniu |
SI1385551T1 (sl) * | 2001-04-06 | 2008-12-31 | Wyeth Five Giralda Farms | Antineoplastiäśne kombinacije, ki vsebujejo cci-779 (derivat rapamicina) skupaj z gemcitabinom ali fluorouracilom |
PL367267A1 (en) * | 2001-06-01 | 2005-02-21 | Wyeth | Antineoplastic combinations |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
US7488313B2 (en) | 2001-11-29 | 2009-02-10 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
JP2003330447A (ja) | 2002-05-15 | 2003-11-19 | Mitsubishi Electric Corp | 画像処理装置 |
KR20080071600A (ko) | 2005-11-21 | 2008-08-04 | 노파르티스 아게 | Mtor 억제제를 사용하는 신경내분비 종양 치료법 |
US9504809B2 (en) | 2011-07-01 | 2016-11-29 | Coloplast A/S | Catheter with a balloon |
EP2606816A1 (en) | 2011-12-22 | 2013-06-26 | Koninklijke Philips Electronics N.V. | A method and system for providing an indication as to the amount of milk remaining in a breast during lactation |
-
2002
- 2002-02-18 LT LTEP14164565.5T patent/LT2762140T/lt unknown
- 2002-02-18 PL PL409579A patent/PL409579A1/pl unknown
- 2002-02-18 NZ NZ527692A patent/NZ527692A/en not_active IP Right Cessation
- 2002-02-18 CA CA2994779A patent/CA2994779C/en not_active Expired - Lifetime
- 2002-02-18 PT PT18155644T patent/PT3351246T/pt unknown
- 2002-02-18 SI SI200231097T patent/SI3342411T1/sl unknown
- 2002-02-18 CN CNB2005100554588A patent/CN1296043C/zh not_active Ceased
- 2002-02-18 KR KR1020057017585A patent/KR20050095906A/ko not_active Application Discontinuation
- 2002-02-18 PT PT101749851T patent/PT2269604T/pt unknown
- 2002-02-18 PT PT181557224T patent/PT3345602T/pt unknown
- 2002-02-18 EP EP18155722.4A patent/EP3345602B1/en not_active Expired - Lifetime
- 2002-02-18 CN CN201410286300.0A patent/CN104083365A/zh active Pending
- 2002-02-18 PL PL02363918A patent/PL363918A1/xx not_active IP Right Cessation
- 2002-02-18 PL PL415000A patent/PL415000A1/pl unknown
- 2002-02-18 CZ CZ2018211A patent/CZ309178B6/cs not_active IP Right Cessation
- 2002-02-18 SK SK5011-2005A patent/SK288545B6/sk unknown
- 2002-02-18 LT LTEP18155724.0T patent/LT3342411T/lt unknown
- 2002-02-18 SI SI200231078A patent/SI2269604T1/sl unknown
- 2002-02-18 MX MXPA03007418A patent/MXPA03007418A/es active IP Right Grant
- 2002-02-18 CZ CZ2019-248A patent/CZ309247B6/cs not_active IP Right Cessation
- 2002-02-18 DK DK14164565.5T patent/DK2762140T3/en active
- 2002-02-18 EP EP14164565.5A patent/EP2762140B1/en not_active Revoked
- 2002-02-18 CZ CZ2010-473A patent/CZ307940B6/cs not_active IP Right Cessation
- 2002-02-18 RU RU2003127391/15A patent/RU2322981C2/ru active
- 2002-02-18 LT LTEP18155644.0T patent/LT3351246T/lt unknown
- 2002-02-18 MX MX2014014346A patent/MX368013B/es unknown
- 2002-02-18 BR BR0207378-1A patent/BR0207378A/pt not_active Application Discontinuation
- 2002-02-18 SI SI200231094T patent/SI3351246T1/sl unknown
- 2002-02-18 EP EP18181342.9A patent/EP3406249A1/en not_active Withdrawn
- 2002-02-18 ES ES18155724T patent/ES2744377T3/es not_active Expired - Lifetime
- 2002-02-18 DK DK18155644.0T patent/DK3351246T3/da active
- 2002-02-18 US US10/468,520 patent/US8410131B2/en active Active
- 2002-02-18 SK SK902019A patent/SK288834B6/sk unknown
- 2002-02-18 AU AU2002250968A patent/AU2002250968C1/en not_active Expired
- 2002-02-18 KR KR1020077022986A patent/KR20070102762A/ko not_active Application Discontinuation
- 2002-02-18 HU HU0303271A patent/HUP0303271A3/hu not_active Application Discontinuation
- 2002-02-18 CA CA2438504A patent/CA2438504C/en not_active Expired - Lifetime
- 2002-02-18 EP EP16186041.6A patent/EP3143995B1/en not_active Expired - Lifetime
- 2002-02-18 EP EP14164561.4A patent/EP2764865A3/en not_active Withdrawn
- 2002-02-18 DK DK16186041.6T patent/DK3143995T3/en active
- 2002-02-18 ES ES16186041T patent/ES2705016T3/es not_active Expired - Lifetime
- 2002-02-18 PT PT141645655T patent/PT2762140T/pt unknown
- 2002-02-18 PT PT101749836T patent/PT2269603E/pt unknown
- 2002-02-18 DK DK10174985.1T patent/DK2269604T3/en active
- 2002-02-18 CN CNA028068440A patent/CN1551767A/zh active Pending
- 2002-02-18 KR KR1020037010870A patent/KR100695846B1/ko active IP Right Review Request
- 2002-02-18 CN CN201410286316.1A patent/CN104116738A/zh active Pending
- 2002-02-18 ES ES10174983.6T patent/ES2543383T3/es not_active Expired - Lifetime
- 2002-02-18 WO PCT/EP2002/001714 patent/WO2002066019A2/en active Application Filing
- 2002-02-18 ES ES14164259.5T patent/ES2640787T3/es not_active Expired - Lifetime
- 2002-02-18 CZ CZ2005-91A patent/CZ307637B6/cs not_active IP Right Cessation
- 2002-02-18 SI SI200231092T patent/SI3143995T1/sl unknown
- 2002-02-18 PL PL414997A patent/PL414997A1/pl unknown
- 2002-02-18 SI SI200231056T patent/SI2269603T1/sl unknown
- 2002-02-18 CZ CZ20032209A patent/CZ303611B6/cs not_active IP Right Cessation
- 2002-02-18 ES ES18155722T patent/ES2921798T3/es not_active Expired - Lifetime
- 2002-02-18 IL IL15742502A patent/IL157425A0/xx unknown
- 2002-02-18 EP EP14164259.5A patent/EP2783686B1/en not_active Revoked
- 2002-02-18 EP EP18155644.0A patent/EP3351246B8/en not_active Revoked
- 2002-02-18 SI SI200231088A patent/SI2762140T1/sl unknown
- 2002-02-18 EP EP10174985.1A patent/EP2269604B1/en not_active Revoked
- 2002-02-18 DK DK10174983.6T patent/DK2269603T3/en active
- 2002-02-18 LT LTEP10174985.1T patent/LT2269604T/lt unknown
- 2002-02-18 ES ES14164565.5T patent/ES2629317T3/es not_active Expired - Lifetime
- 2002-02-18 EP EP18155724.0A patent/EP3342411B1/en not_active Expired - Lifetime
- 2002-02-18 EP EP20100174983 patent/EP2269603B1/en not_active Revoked
- 2002-02-18 CA CA2860306A patent/CA2860306C/en not_active Expired - Lifetime
- 2002-02-18 ES ES10174985.1T patent/ES2600304T3/es not_active Expired - Lifetime
- 2002-02-18 ES ES18155644T patent/ES2728739T3/es not_active Expired - Lifetime
- 2002-02-18 SK SK1038-2003A patent/SK288546B6/sk unknown
- 2002-02-18 PT PT18155724T patent/PT3342411T/pt unknown
- 2002-02-18 CN CN201410469536.8A patent/CN104274442A/zh active Pending
- 2002-02-18 PL PL414996A patent/PL231418B1/pl unknown
- 2002-02-18 JP JP2002565579A patent/JP2004525899A/ja active Pending
- 2002-02-18 DK DK18155724.0T patent/DK3342411T3/da active
- 2002-02-18 SK SK50003-2016A patent/SK288524B6/sk unknown
- 2002-02-18 LT LTEP16186041.6T patent/LT3143995T/lt unknown
- 2002-02-18 SK SK50008-2016A patent/SK288630B6/sk unknown
- 2002-02-18 PT PT16186041T patent/PT3143995T/pt unknown
- 2002-02-18 EP EP02719864A patent/EP1363627A2/en not_active Withdrawn
- 2002-02-19 TW TW095103554A patent/TW200626151A/zh unknown
- 2002-02-19 TW TW091102797A patent/TWI334350B/zh not_active IP Right Cessation
-
2003
- 2003-08-14 IL IL157425A patent/IL157425A/en active IP Right Grant
- 2003-08-18 NO NO20033651A patent/NO333105B1/no not_active IP Right Cessation
- 2003-08-19 MX MX2019010879A patent/MX2019010879A/es unknown
-
2004
- 2004-04-15 HK HK11101882.6A patent/HK1146247A1/xx not_active IP Right Cessation
- 2004-04-15 HK HK18109528.2A patent/HK1250019A1/zh not_active IP Right Cessation
- 2004-04-15 HK HK14110193.8A patent/HK1197723A1/zh not_active IP Right Cessation
- 2004-04-15 HK HK18109752.9A patent/HK1250336B/zh not_active IP Right Cessation
- 2004-04-15 HK HK11101880.8A patent/HK1146245A1/zh not_active IP Right Cessation
- 2004-04-15 HK HK14112655.5A patent/HK1198946A1/xx not_active IP Right Cessation
- 2004-04-15 HK HK18109527.3A patent/HK1250018B/zh not_active IP Right Cessation
-
2005
- 2005-03-01 RU RU2005105664/15A patent/RU2325906C2/ru active
-
2006
- 2006-11-16 RU RU2006140514/15A patent/RU2445093C2/ru not_active IP Right Cessation
-
2007
- 2007-08-06 JP JP2007204409A patent/JP2007284454A/ja active Pending
-
2009
- 2009-11-16 IL IL202155A patent/IL202155A/en active IP Right Grant
-
2011
- 2011-09-22 RU RU2011138835/15A patent/RU2483727C1/ru active
-
2012
- 2012-02-23 US US13/403,474 patent/US20130059877A1/en not_active Abandoned
- 2012-02-23 US US13/403,578 patent/US8436010B2/en not_active Expired - Lifetime
- 2012-04-18 NO NO20120451A patent/NO335134B1/no not_active IP Right Cessation
- 2012-04-26 JP JP2012101519A patent/JP5775022B2/ja not_active Expired - Lifetime
- 2012-05-31 IL IL220095A patent/IL220095A/en active IP Right Grant
- 2012-05-31 IL IL220096A patent/IL220096A/en active IP Right Grant
- 2012-07-11 US US13/546,686 patent/US8778962B2/en not_active Expired - Lifetime
-
2013
- 2013-01-09 NO NO20130045A patent/NO334646B1/no not_active IP Right Cessation
- 2013-04-26 RU RU2013119705A patent/RU2665138C2/ru active
- 2013-05-14 US US13/893,589 patent/US20130244951A1/en not_active Abandoned
- 2013-05-14 US US13/893,537 patent/US20130253000A1/en not_active Abandoned
- 2013-06-27 US US13/928,583 patent/US20130296359A1/en not_active Abandoned
- 2013-06-27 US US13/928,891 patent/US8877771B2/en not_active Expired - Fee Related
- 2013-09-24 RU RU2013143306A patent/RU2659725C2/ru active
- 2013-10-30 IL IL229160A patent/IL229160B/en active IP Right Grant
- 2013-10-30 IL IL229158A patent/IL229158A/en active IP Right Grant
- 2013-10-30 IL IL229156A patent/IL229156A/en active IP Right Grant
- 2013-10-30 IL IL229159A patent/IL229159A0/en unknown
- 2013-10-30 IL IL229157A patent/IL229157A0/en unknown
- 2013-11-19 NO NO20131544A patent/NO336208B1/no not_active IP Right Cessation
- 2013-11-19 NO NO20131546A patent/NO336110B1/no not_active IP Right Cessation
- 2013-11-19 NO NO20131547A patent/NO336581B1/no not_active IP Right Cessation
- 2013-11-19 NO NO20131545A patent/NO336428B1/no not_active Application Discontinuation
- 2013-12-19 US US14/134,419 patent/US20140105895A1/en not_active Abandoned
-
2014
- 2014-05-02 JP JP2014095034A patent/JP5873128B2/ja not_active Expired - Lifetime
- 2014-06-02 JP JP2014114297A patent/JP5879391B2/ja not_active Expired - Lifetime
- 2014-06-02 JP JP2014114296A patent/JP2014208657A/ja not_active Withdrawn
-
2015
- 2015-03-18 NO NO2015010C patent/NO2015010I1/no unknown
- 2015-04-08 JP JP2015079430A patent/JP6333766B2/ja not_active Expired - Lifetime
- 2015-04-09 NO NO20150413A patent/NO20150413L/no not_active Application Discontinuation
- 2015-06-24 NO NO20150831A patent/NO340553B1/no not_active IP Right Cessation
- 2015-07-08 NO NO20150895A patent/NO339240B1/no not_active IP Right Cessation
- 2015-08-13 CY CY20151100711T patent/CY1116616T1/el unknown
- 2015-11-17 LU LU92880C patent/LU92880I2/xx unknown
- 2015-11-19 CY CY2015044C patent/CY2015044I2/el unknown
-
2016
- 2016-06-28 US US15/195,018 patent/US20160303092A1/en not_active Abandoned
- 2016-07-29 JP JP2016149701A patent/JP6310970B2/ja not_active Expired - Lifetime
- 2016-08-24 NO NO20161348A patent/NO340924B1/no not_active IP Right Cessation
- 2016-10-21 CY CY20161101060T patent/CY1118316T1/el unknown
- 2016-11-23 LU LU93320C patent/LU93320I2/fr unknown
- 2016-11-28 LT LTPA2016035C patent/LTC2269604I2/lt unknown
- 2016-12-20 CY CY2016047C patent/CY2016047I1/el unknown
-
2017
- 2017-01-06 JP JP2017001065A patent/JP6383814B2/ja not_active Expired - Lifetime
- 2017-02-20 IL IL250676A patent/IL250676B/en active IP Right Grant
- 2017-03-19 IL IL251270A patent/IL251270B/en active IP Right Grant
- 2017-05-16 NO NO20170803A patent/NO343599B1/no not_active IP Right Cessation
- 2017-06-22 CY CY20171100668T patent/CY1119029T1/el unknown
-
2018
- 2018-02-08 JP JP2018021352A patent/JP6349474B2/ja not_active Expired - Lifetime
- 2018-02-08 JP JP2018021353A patent/JP6349475B2/ja not_active Expired - Lifetime
- 2018-02-08 JP JP2018021354A patent/JP6349476B2/ja not_active Expired - Lifetime
- 2018-05-31 IL IL259724A patent/IL259724B/en unknown
- 2018-06-08 RU RU2018121314A patent/RU2018121314A/ru not_active Application Discontinuation
- 2018-07-06 JP JP2018129096A patent/JP2018168188A/ja not_active Withdrawn
- 2018-07-30 RU RU2018127821A patent/RU2018127821A/ru not_active Application Discontinuation
-
2019
- 2019-01-10 CY CY20191100021T patent/CY1121314T1/el unknown
- 2019-03-04 NO NO20190290A patent/NO20190290A1/no not_active Application Discontinuation
- 2019-06-04 LT LTPA2019511C patent/LTPA2019511I1/lt unknown
- 2019-06-04 CY CY2019030C patent/CY2019030I1/el unknown
- 2019-06-04 LU LU00122C patent/LUC00122I2/fr unknown
- 2019-06-14 CY CY20191100619T patent/CY1121715T1/el unknown
- 2019-09-03 CY CY20191100925T patent/CY1121983T1/el unknown
- 2019-11-21 LT LTPA2019521 patent/LTPA2019521I1/lt unknown
- 2019-11-21 CY CY2019043C patent/CY2019043I1/el unknown
-
2020
- 2020-02-20 LT LTPA2020503C patent/LTPA2020503I1/lt unknown
- 2020-02-20 CY CY2020005C patent/CY2020005I1/el unknown
- 2020-05-26 JP JP2020091227A patent/JP6904640B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2629317T3 (es) | Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina | |
ES2952265T3 (es) | Terapia combinada que comprende un inhibidor de Raf y trametinib | |
EP3066101B1 (en) | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors | |
CA2915005C (en) | Use of eribulin and lenvatinib as combination therapy for treatment of cancer | |
KR20180132939A (ko) | 암 치료를 위한 조합 요법 | |
JP2012515184A (ja) | 大腸がんの治療方法 | |
BR112020015520A2 (pt) | terapia de combinação para câncer com complexo de anel macrocíclico pentaaza e agente anticâncer à base de platina | |
WO2015142867A1 (en) | Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells | |
EP3151864A1 (en) | Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy | |
US20210308111A1 (en) | Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers | |
AU2014279721A1 (en) | Pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent | |
ZA200508696B (en) | Use of irinotecan for treatment of resistant breast cancer | |
WO2019002542A1 (en) | COMBINATION OF AN INHIBITOR OF MPS1 AND A TAXANE COMPOUND, USES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | |
US20220184034A1 (en) | Methods for treating cutaneous metastatic cancers | |
WO2023009500A1 (en) | Pentaaza macrocyclic ring complex for enhanced surgical treatment | |
KR20240004543A (ko) | 혈액암을 치료하는 방법 | |
US20030139430A1 (en) | Use of organic compounds | |
JP2023050198A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
EP4203963A1 (en) | Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma | |
EP2144607B1 (en) | Compositions for contributing to the treatment of cancers | |
JP2006518355A (ja) | インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法 | |
EA040162B1 (ru) | Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции |